These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 16415100

  • 1. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [Abstract] [Full Text] [Related]

  • 2. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, Takeshima T, Gyobu H, Kawarada Y, Kondo S, Akira S, Katoh H, Ikeda H, Nishimura T.
    Cancer Res; 2004 Dec 01; 64(23):8754-60. PubMed ID: 15574787
    [Abstract] [Full Text] [Related]

  • 3. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Cancer Res; 2006 Feb 01; 66(3):1809-17. PubMed ID: 16452242
    [Abstract] [Full Text] [Related]

  • 4. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y, Wakita D, Chamoto K, Narita Y, Matsubara N, Kitamura H, Nishimura T.
    Int Immunol; 2007 Feb 01; 19(2):151-61. PubMed ID: 17189593
    [Abstract] [Full Text] [Related]

  • 5. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H, Okamoto T, Kanzaki M, Inozume T, Shibagaki N, Shimada S.
    Br J Dermatol; 2010 Jan 01; 162(1):29-41. PubMed ID: 19863514
    [Abstract] [Full Text] [Related]

  • 6. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.
    Clin Cancer Res; 1999 May 01; 5(5):1173-82. PubMed ID: 10353754
    [Abstract] [Full Text] [Related]

  • 7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007 May 01; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 8. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L, Sad S, Patel GB, Sprott GD.
    Cancer Res; 2003 May 15; 63(10):2526-34. PubMed ID: 12750276
    [Abstract] [Full Text] [Related]

  • 9. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V, Graser A, Müller R, Kontermann RE, Konur A.
    J Immunother; 2006 May 15; 29(3):294-305. PubMed ID: 16699372
    [Abstract] [Full Text] [Related]

  • 10. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 11. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
    Trujillo-Vargas CM, Mayer KD, Bickert T, Palmetshofer A, Grunewald S, Ramirez-Pineda JR, Polte T, Hansen G, Wohlleben G, Erb KJ.
    Clin Exp Allergy; 2005 Aug 15; 35(8):1003-13. PubMed ID: 16120081
    [Abstract] [Full Text] [Related]

  • 12. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E, Kennedy R, Celis E.
    Cancer Res; 2003 Jun 15; 63(12):3281-8. PubMed ID: 12810660
    [Abstract] [Full Text] [Related]

  • 13. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J.
    Clin Immunol; 2004 Jul 15; 112(1):35-44. PubMed ID: 15207780
    [Abstract] [Full Text] [Related]

  • 14. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway.
    Xu W, Tamura T, Takatsu K.
    Int Immunopharmacol; 2008 Feb 15; 8(2):351-61. PubMed ID: 18182251
    [Abstract] [Full Text] [Related]

  • 15. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
    Kojima N, Biao L, Nakayama T, Ishii M, Ikehara Y, Tsujimura K.
    J Control Release; 2008 Jul 02; 129(1):26-32. PubMed ID: 18485512
    [Abstract] [Full Text] [Related]

  • 16. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
    Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM.
    Vaccine; 2006 Jun 12; 24(24):5235-44. PubMed ID: 16675074
    [Abstract] [Full Text] [Related]

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 12; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 18. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N, Mukherjee S, Das L, Das PK.
    Eur J Immunol; 2003 Jun 12; 33(6):1508-18. PubMed ID: 12778468
    [Abstract] [Full Text] [Related]

  • 19. Antimetastatic effect of CpG DNA mediated by type I IFN.
    Hafner M, Zawatzky R, Hirtreiter C, Buurman WA, Echtenacher B, Hehlgans T, Männel DN.
    Cancer Res; 2001 Jul 15; 61(14):5523-8. PubMed ID: 11454702
    [Abstract] [Full Text] [Related]

  • 20. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.
    Vaccine; 2006 Mar 10; 24(11):1880-8. PubMed ID: 16300869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.